ORIC reports Q4 2025 cash of $392.3M; positive Phase 1b data for rinzimetostat and enozertinib

Oric Pharmaceuticals, Inc.

2025-FY EPS reported -$1.47

Cash and investments $392.3M at Dec 31, 2025; proforma $412.3M after $20M ATM in 2026; runway into 2H 2028.
Raised $264M from healthcare specialist funds in 2025 via private placement ($124.4M) and ATM ($117.6M).
R&D expenses Q4 2025 $25.9M (down 19% YoY); full year 2025 $109.8M (down 4% YoY).
Rinzimetostat Phase 1b: 55% PSA50, 20% PSA90, 76% ctDNA reduction; favorable safety vs competitors.
Enozertinib Phase 1b: 67% ORR in 1L EGFR exon20, 80% ORR in 1L EGFR PACC; 100% intracranial ORR.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.